Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Surgery Versus Intra-lesional Sclerosis With Polidocanol (Aetoxisclerol) in Labial Venous Malformations in Children and Adults (SASOV)

10. listopadu 2026 aktualizováno: University Hospital, Tours

Surgery Versus Intra-lesional Sclerosis With Polidocanol (Aetoxisclerol) in Labial Venous Malformations in Children and Adults: a Randomized Controlled Trial

The goal of this clinical trial is to learn if Surgery works better than Intra-lesional Sclerosis With Polidocanol to treat Labial Venous Malformations in Children and Adults. It will also learn about the safety of both approaches. The main questions it aims to answer are:

  • Does Surgery has greater Global efficacy, including (including lesion volume reduction, scar quality, and lip symmetry) than Intra-lesional Sclerosis With Polidocanol?
  • What complications do participants have when undergoing Surgery or Intra-lesional Sclerosis With Polidocanol? Researchers will compare surgery to Intra-lesional Sclerosis With Polidocanol.

Participants will be randomized to one of two treatment strategies:

  • Experimental group: Surgical excision of the labial venous malformation (VM).
  • Control group: Sclerotherapy strategy consisting of one or two sessions of intralesional polidocanol 3% injection.

Patients will be identified and recruited during multidisciplinary vascular anomalies clinics. The study protocol will be explained to eligible patients and their families. After obtaining written informed consent (or consent from both parents together with the child's assent, when applicable), participants will be enrolled in the study.

Following enrollment, participants will be randomly assigned to one of the two parallel treatment groups. A baseline assessment will be performed, and patients will receive a patient diary to record subjective outcomes, including pain, during the pre-intervention period until the date of the procedure.

Study follow-up visits will take place at 1 month (telemedicine visit), 3 months, and 12 months after treatment. Outcome assessments will be performed at each scheduled follow-up visit.

Přehled studie

Typ studie

Intervenční

Zápis (Odhadovaný)

50

Fáze

  • Fáze 3

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní záloha kontaktů

Studijní místa

      • Paris, Francie
      • Paris, Francie
        • Necker
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Olivia BOCCARA, MD
      • Tours, Francie

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

4 roky a starší (Dítě, Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  • Age ≥ 4 years
  • Symptomatic venous malformation of the lower and/or upper lip
  • Venous pocket with an area of between 10 and 50 mm²
  • No history of surgery or interventional radiology in the area within the two years prior to inclusion
  • Suitable for sclerotherapy and surgery
  • Patient covered by the National Health Service
  • Informed, written consent from the child's legal guardians or from the participant themselves if they are of legal age

Exclusion Criteria:

  • Pregnant or breastfeeding women
  • Women of childbearing age not using effective contraception throughout the study
  • Patients under guardianship or curatorship, or subject to a court-ordered protective measure
  • Other vascular abnormalities
  • Contraindications to MRI
  • Contraindications to Aetoxisclerol®
  • Contraindications to general anaesthesia
  • Contraindications to surgery

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Singl

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Surgical strategy

Experimental group: Surgical strategy for the excision of the superficial venous malformation (SVM). The surgery involves either partial reconstructive excision or complete excision of the SVM, depending on its size. The aim is to restore symmetry to the affected side of the lip in order to correct functional impairments and aesthetic effects.

The surgery is performed under local or general anaesthesia (depending on the size of the SVM and the patient's age). Various coagulation devices (monopolar forceps with a Colorado tip, bipolar scissors, etc.) are used to section and dissect the SVM and to control haemostasis.

Aktivní komparátor: Sclerotherapy strategy

Control group: Sclerotherapy strategy comprising one to two sessions of intra-lesional sclerotherapy with 3% polidocanol (Aetoxisclerol).

The procedure may be carried out under local or general anaesthesia, depending on the patient's age, anticipated tolerance and in accordance with standard practice at the centre. The patient is positioned in the supine position. Following manual and visual localisation of the target lesion, one or more needles of 30/100th to 18G gauge are inserted, and their position within the lesion is confirmed by gentle aspiration, which should yield blood without resistance. The injection of an iodinated contrast medium suitable for intravenous use, to characterise the drainage and under fluoroscopic guidance in the angiography suite, is recommended but not mandatory. Once in place, ≤ 2 mg/kg of polidocanol is injected per session, i.e. ≤ 0.067 mL/kg of 3% solution distributed amongst the needles (1/2 to 2 ampoules), until thrombosis occurs, significant tension is felt in the lesion, or pain develops.

Sclerotherapy may be repeated if necessary between 3 and 6 months after the first session.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Global change
Časové okno: From enrollment to Month 12 post intervention

Global change will be assessed 12 months after the intervention using a Likert scale ranging from -5 to +5 (0 = no improvement or worsening, higher scores mean better outcome), based on standardized pre- and post-intervention photographs. Assessments will be performed by an independent review panel comprising three physicians (one surgeon, one dermatologist, and one interventional radiologist) and one patient with a labial VM who did not participate in the study. The evaluation will be performed blinded to treatment allocation and will encompass changes in lesion volume, scar quality, and lip symmetry. A standardized photography protocol will be used. This primary endpoint (photograph-based assessment by an independent review panel) was selected to limit bias related to the open-label nature of the study, consistent with a PROBE design (Prospective Randomized Open, Blinded Endpoint).

From enrollment to Month 12 post intervention

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Aesthetic impact of the venous malformation
Časové okno: Month 0 and Month 12

Assessment of aesthetic burden using a 0 to 10 visual analogue scale (VAS) with higher scores mean worse outcome, measured at baseline and 12 months after the intervention.

Month 0 and Month 12
Functional impact: overall mouth function
Časové okno: Month 0 and Month 12

Functional impact assessed using a 0 to 10 Visual Analogue Scale (VAS) for overall mouth function, with higher scores mean worse outcome

Month 0 and Month 12
Functional impact: lip continence
Časové okno: Month 0 and Month 12

Quantification of lip continence using a self-administered drooling questionnaire (Drooling Severity and Frequency Scale [DSFS]), score ranging from 2 to 9 with higher scores mean worse outcome

Month 0 and Month 12
Functional impact: speech intelligibility
Časové okno: Month 0 and Month 12

Speech intelligibility assessed using a self-administered questionnaire measuring speech-related intelligibility, the Intelligibility in Context Scale (ICS). Score ranging from 7 to 35, with higher scores mean better outcome

Month 0 and Month 12
Overall patient satisfaction: Likert scale
Časové okno: From enrollment to Month 12

Overall patient satisfaction assessed with a Likert scale ranging from -5 to +5 (0 = no improvement and no worsening), higher scores mean better outcome

From enrollment to Month 12
Overall patient satisfaction: Goal Attainment Scale
Časové okno: Month 12

Using achievement of personalized goals (maximum of three), predefined by the patient together with the investigator, assessed with the Goal Attainment Scale (GAS; scores ranging from -2 to +2, with higher scores mean better outcome). The Goal Attainment Scale (GAS) is a method for measuring treatment effectiveness by creating patient-specific outcome scales that are predefined before study participation. GAS aims to identify goals that are meaningful to the patient and related to their daily activities and individual priorities (Steinbook RM, 1977; DOI: 10.1001/archpsyc.1977.01770200061005).

Month 12
Number of painful days: Total number of painful days
Časové okno: The month (30 days) preceding the intervention, the month following the intervention, and the month preceding the 12-month post intervention visit (M12)

Total number of painful days assessed using either a patient diary or the online ePRO portal.

The month (30 days) preceding the intervention, the month following the intervention, and the month preceding the 12-month post intervention visit (M12)
Number of painful days: Number of painful days with a VAS pain score > 3/10
Časové okno: The month (30 days) preceding the intervention, the month following the intervention, and the month preceding the 12-month post-intervention visit (M12)

Number of painful days with a VAS pain score > 3/10 assessed using either a patient diary or the online ePRO portal.

The month (30 days) preceding the intervention, the month following the intervention, and the month preceding the 12-month post-intervention visit (M12)
Venous Malformation volume on MRI
Časové okno: Month 0 and Month 12

Venous malformation volume assessed before the intervention (within 6 months prior to treatment) and 12 months after the intervention (performed as part of routine care). Volumetric assessment will be conducted using a semi-automated thresholding method. Image analysis will be centralized and performed by an independent radiologist blinded to treatment allocation.

Month 0 and Month 12
Coagulation: D-dimer
Časové okno: Month 12

D-dimer

Month 12
Coagulation: fibrinogen level
Časové okno: Month 12

Fibrinogen level

Month 12
Adverse events including complications
Časové okno: From enrollment to Month 12

Safety including adverse events and complications, recorded using a patient diary or the online ePRO portal

From enrollment to Month 12
Acceptability of the interventions
Časové okno: Month 1, Month 3 , and Month 12

Acceptability of the interventions for the patient (or for parents in children aged < 6 years), assessed using a 0 to 10 Visual Analogue Scale (VAS), with higher scores mean worse outcome

Month 1, Month 3 , and Month 12
Healthcare costs
Časové okno: From enrollment to Month 12 following the intervention

In each arm, patients' healthcare utilization related to the procedure and outpatient care will be measured using hospital databases and a patient diary, then valued in euros from the perspective of the healthcare system.

From enrollment to Month 12 following the intervention

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

1. ledna 2027

Primární dokončení (Odhadovaný)

1. července 2028

Dokončení studie (Odhadovaný)

1. ledna 2030

Termíny zápisu do studia

První předloženo

15. září 2026

První předloženo, které splnilo kritéria kontroly kvality

10. listopadu 2026

První zveřejněno (Aktuální)

12. listopadu 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

12. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

10. listopadu 2026

Naposledy ověřeno

1. listopadu 2026

Více informací

Termíny související s touto studií

Klíčová slova

Další identifikační čísla studie

  • DR240317
  • 2025 (Grant/smlouva NIH USA)
  • 2025-521374-34-00 (Ctis)

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NE

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit